Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per indagare la sicurezza e la tollerabilità del QEQ278 per via endovenosa in pazienti con tumori solidi avanzati

9 novembre 2026 aggiornato da: Novartis Pharmaceuticals

Uno studio di fase I/Ib, in aperto, multicentrico, su QEQ278 in pazienti con tumori solidi avanzati

To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.

Panoramica dello studio

Descrizione dettagliata

This study is an open-label, phase I/Ib, multi-center study of QEQ278 as a single agent, consisting of a dose escalation part followed by a dose expansion part.

In the dose escalation part of the study, patients with non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), renal cell carcinoma (RCC), or human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) will be treated with QEQ278 single agent until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.

The study may enter the dose expansion, after an MTD(s) and/or RD(s) is declared in the dose escalation.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

30

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Brussels, Belgio, 1200
        • Novartis Investigative Site
      • Paris, Francia, 75231
        • Novartis Investigative Site
      • Essen, Germania, 45147
        • Novartis Investigative Site
    • Chiba
      • Kashiwa, Chiba, Giappone, 2778577
        • Novartis Investigative Site
    • MI
      • Milan, MI, Italia, 20133
        • Novartis Investigative Site
      • Singapore, Singapore, 168583
        • Novartis Investigative Site
      • Barcelona, Spagna, 08035
        • Novartis Investigative Site
    • California
      • Los Angeles, California, Stati Uniti, 90095
        • University of California LA
    • Florida
      • Fort Myers, Florida, Stati Uniti, 33901
        • Florida Cancer Specialists
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Stati Uniti, 02114
        • Massachusetts General Hospital Dept. of Mass General Hospital
      • Taipei, Taiwan, 10002
        • Novartis Investigative Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 100 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Signed informed consent must be obtained prior to participation in the study.
  • Adult men and women ≥ 18 years of age.
  • Histologically confirmed and documented advanced malignancies (locally advanced malignancies, non-curable by surgery or radiotherapy and metastatic disease). Disease must be measurable, including presence of at least one measurable lesion, as determined by RECIST v1.1.
  • In the opinion of the treating investigator, patients must have received, but are not benefitting from standard therapies, be intolerant or ineligible to receive such therapy, or have no standard therapy option for the respective disease types (diseases listed below), as well as any other therapies deemed to be standard by local/institutional standard.
  • Non-small cell lung cancer
  • Esophageal squamous cell carcinoma
  • Renal cell carcinoma
  • HPV-associated head and neck squamous cell carcinoma
  • Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. The patient must be willing to undergo a new tumor biopsy at screening and during treatment.

Exclusion Criteria:

  • Active previously documented or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur should not be excluded. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
  • Patients with a history of or current interstitial lung disease or pneumonitis ≥ Grade 2.
  • Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity
  • Clinically significant cardiac disease or risk factors at screening
  • Insufficient bone marrow function at screening:
  • Infections:
  • Known history of testing positive for Human Immunodeficiency Virus infection.
  • Active Hepatitis B and / or Hepatitis C.
  • Active, documented COVID-19 infection
  • Known history of tuberculosis
  • Any serious uncontrolled infection (acute or chronic).
  • Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, and ophthalmic steroids are allowed.

Other protocol-defined inclusion/exclusion criteria may apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Part 1: Dose escalation

Dose escalation with QEQ278 single agent

Intravenous dosing of QEQ278

Sperimentale: Part 2: Dose expansion

Dose expansion with QEQ278 single agent

Intravenous dosing of QEQ278

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence and nature of Dose Limiting Toxicities (DLTs) during the DLT evaluation period for single agent QEQ278
Lasso di tempo: 28 days

A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT evaluation period and meets the criteria defined in the study protocol.

28 days
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Lasso di tempo: Up to 31 months

Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), including changes in laboratory values, vital signs, and electrocardiograms (ECGs) qualifying and reported as AEs.

Up to 31 months
Frequency of dose interruptions, reductions
Lasso di tempo: Up to 30 months

Number of dose interruptions of QEQ278 and number of dose reductions of QEQ278

Up to 30 months
Dose intensity
Lasso di tempo: Up to 30 months

Dose intensity of QEQ278 is defined as the ratio of actual cumulative dose received and actual duration of exposure.

Up to 30 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall response rate (ORR) per RECIST v1.1
Lasso di tempo: Up to 30 months

ORR is defined as the proportion of patients with a confirmed BOR of complete response (CR) or partial response (PR) by local investigator review as per RECIST v1.1.

Up to 30 months
Disease control rate (DCR) per RECIST v1.1
Lasso di tempo: Up to 30 months

DCR is defined as the proportion of patients with a confirmed best overall response (BOR) of CR or PR or stable disease (SD) by local investigator review as per RECIST v1.1.

Up to 30 months
Duration of Response (DOR) per RECIST v1.1
Lasso di tempo: Up to 30 months

DOR is defined as the time form the date of the first documented response (CR or PR) to the date of the first documented progression by local investigator review as per RECIST v1.1 or death due to underlying cancer.

Up to 30 months
Progression-free survival (PFS) per RECIST v 1.1
Lasso di tempo: Up to 30 months

PFS is defined as the time from the date of start of treatment to the date of the first documented progression by local investigator review as per RECIST v1.1, or death due to any cause.

Up to 30 months
Peak serum concentration (Cmax) of QEQ278
Lasso di tempo: During first 168 days of treatment

The maximum (peak) serum drug concentration after single dose administration

During first 168 days of treatment
Area under the concentration time curve (AUC) last of QEQ278
Lasso di tempo: During first 168 days of treatment

The AUC from time zero to the last measurable concentration sampling time

During first 168 days of treatment
Area under the concentration time curve (AUC) infinity of QEQ278
Lasso di tempo: During first 168 days of treatment

The AUC from time zero to infinity

During first 168 days of treatment
Time to reach peak serum concentration (Tmax) of QEQ278
Lasso di tempo: During first 168 days of treatment

The time to reach maximum (peak) serum drug concentration after single dose administration

During first 168 days of treatment
Elimination half-life (T1/2) of QEQ278
Lasso di tempo: During first 168 days of treatment

The elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve

During first 168 days of treatment
Total body clearance (CL) of QEQ278
Lasso di tempo: During first 168 days of treatment

The total body clearance of drug from the serum

During first 168 days of treatment
Volume of distribution (Vz) of QEQ278
Lasso di tempo: During first 168 days of treatment

The apparent volume of distribution during terminal phase

During first 168 days of treatment
Incidence of anti-drug antibody (ADA)
Lasso di tempo: Day 1 and 15

Immunogenicity of QEQ278

Day 1 and 15

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 aprile 2023

Completamento primario (Effettivo)

26 gennaio 2026

Completamento dello studio (Effettivo)

26 gennaio 2026

Date di iscrizione allo studio

Primo inviato

14 luglio 2022

Primo inviato che soddisfa i criteri di controllo qualità

14 luglio 2022

Primo Inserito (Effettivo)

18 luglio 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 febbraio 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi